SB-236057

Clinical data
Other names	SB236057; SB-236057-A; SB-236057A; SB236057A
Routes of administration	Oral
Drug class	Serotonin 5-HT1B receptor inverse agonist
ATC code	None
Identifiers
IUPAC name 1'-ethyl-5-[2'-methyl-4'-(5-methyl-1,3,4-oxadiazolyl-2-yl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro(furo[2,3-f]indole-3,4'-piperidine)
CAS Number	180083-49-2 Y
PubChem CID	5311426
IUPHAR/BPS	3231
ChemSpider	4470914
UNII	6W25PBE4MD
ChEMBL	ChEMBL1628625
CompTox Dashboard (EPA)	DTXSID0047321
Chemical and physical data
Formula	C33H34N4O3
Molar mass	534.660 g·mol−1
3D model (JSmol)	Interactive image
SMILES n5nc(C)oc5-c(cc2C)ccc2-c6ccc(cc6)C(=O)N(CCc1cc3OC7)c1cc3C7(CC4)CCN4CC
InChI InChI=1S/C33H34N4O3/c1-4-36-15-12-33(13-16-36)20-39-30-18-25-11-14-37(29(25)19-28(30)33)32(38)24-7-5-23(6-8-24)27-10-9-26(17-21(27)2)31-35-34-22(3)40-31/h5-10,17-19H,4,11-16,20H2,1-3H3 Key:WXAKEEQOWUHGCI-UHFFFAOYSA-N

SB-236057 is a compound which is a potent and selective inverse agonist for the serotonin receptor 5-HT_1B, acting especially at 5-HT_1B autoreceptors on nerve terminals. It produces a rapid increase in serotonin levels in the brain, and was originally researched as a potential antidepressant.^[2][3] However subsequent research found that SB-236,057 also acts as a potent teratogen, producing severe musculoskeletal birth defects when rodents were exposed to it during pregnancy. This has made it of little use for research into its original applications, yet has made it useful for studying embryonic development instead.^[4][5] The drug was under development by GlaxoSmithKline for the treatment of major depressive disorder in the 2000s and reached the preclinical research stage of development but was never marketed.

• List of investigational antidepressants
• AR-A000002
• GR-55562
• GR-127935
• SB-216641